Monograph
J07BB03 - Influenza, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Decreased appetite is reported as a very common side effect and may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Based on the pharmacokineticsof the influeza vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Prophylaxis of influenza in children and adolescents between 2-18 years.
The live attenuated influenza vaccine is for nasal administration and is given as one divided dose in both nostrils.
Metabolism and pharmacokinetics
The influenza vaccine is not metabolized by the Cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Fluenz. (Last edition: 29.07. 2016).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024